PT  - JOURNAL ARTICLE
AU  - Effat Davoudi-Monfared
AU  - Hamid Rahmani
AU  - Hossein Khalili
AU  - Mahboubeh Hajiabdolbaghi
AU  - Mohamadreza Salehi
AU  - Ladan Abbasian
AU  - Hossein Kazemzadeh
AU  - Mir Saeed Yekaninejad
TI  - Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
AID  - 10.1101/2020.05.28.20116467
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.28.20116467
4099  - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20116467.short
4100  - http://medrxiv.org/content/early/2020/05/30/2020.05.28.20116467.full
AB  - Objectives To the best of our knowledge, there is no published study regarding use of IFN β-1a in the treatment of severe COVID-19. In this randomized clinical trial efficacy and safety of IFN β-1a has been evaluated in patients with severe COVID-19.Methods Forty-two patients in the interferon group received IFN β-1a in addition to the standard of care. Each 44 micrograms/ml (12 million IU/ml) of interferon β-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group received only the standard of care. Primary outcome of study was time to reach clinical response. Secondary outcomes duration of hospital stay, length of ICU stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects and complications during the hospitalization.Results As primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 ± 5.8 vs. 8.3 ± 4.9 days respectively, P = 0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR = 2.5; 95% CI: 1.05-6.37). The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p = 0.015). Early administration significantly reduced mortality (OR = 13.5; 95% CI: 1.5–118).Conclusion Although did not change time to reach the clinical response, adding to the standard of care significantly increased discharge rate on day 14 and decreased 28-day mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRCT20100228003449N28Funding StatementThe authors have not received any fund about this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Tehran University of Medical Sciences approved the study (approved ID: IR.TUMS.VCR.REC.1398.1052).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available per request.